MEDNAX Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
MEDNAX (MD) Tops Q3 EPS by 1c, Revenues Beat; Offers Q4 EPS Outlook
November 1, 2019 6:01 AM EDTMEDNAX (NYSE: MD) reported Q3 EPS of $0.91, $0.01 better than the analyst estimate of $0.90. Revenue for the quarter came in at $889 million versus the consensus estimate of $876.24 million.
For the 2019 third quarter, MEDNAX reported the following results from continuing operations:
Net revenue of $889 million;GAAP net loss of $1.26 billion; andAdjusted EBITDA of $133 million.Our operating results for the third quarter were in line with our expectations, said Roger J. Medel, M.D., Chief Executive Officer of MEDNAX. Revenue growth reflected strong patient volumes across our core medical groups, while clinical and... More
